A rare case of community acquired meningitis caused by multidrug resistant Acinetobacter baumannii in Bengaluru India

Rahul Shil; Saikat Das; Girish Chandra M. S.

doi:10.18203/2394-6040.ijcmph20254064

Authors

Rahul Shil Department of MSN (Neuroscience), PES University, Bengaluru, Karnataka, India
Saikat Das Department of Nursing Sciences, Shri Varchas College of Nursing, Bengaluru, Karnataka, India
Girish Chandra M. S. Department of MSN (Cardiovascular and Thoracic), Shri Varchas College of Nursing, Bengaluru, Karnataka, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20254064

Keywords:

Acinetobacter baumannii, Community acquired meningitis, Antibiotics, Hospital acquired infection

Abstract

Acinetobacter baumannii can be a potentially life-threatening cause of severe community-acquired meningitis outside healthcare facilities and as a nosocomial infection following neurosurgical procedures in intensive care units (ICUs). Despite the availability of potent newer antibiotics, mortality and complications remain high in India, ranging from 16% to 32%. Community-acquired meningitis caused by A. baumannii is relatively rare, and proper antibiotic usage and adherence to infection control protocols in hospitals should be prioritized. In this case study, we report a case of community-acquired meningitis caused by A. baumannii in Bangalore without any prior history of neurosurgical complications or trauma.

Metrics

Metrics Loading ...

References

Lin MF. Antimicrobial resistance inAcinetobacter baumannii: From bench to bedside. World Journal of Clinical Cases. 2014;2(12):787. DOI: https://doi.org/10.12998/wjcc.v2.i12.787

Antunes LCS, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2013;71(3):292-301. DOI: https://doi.org/10.1111/2049-632X.12125

Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis. 2008;197(8):1079-81. DOI: https://doi.org/10.1086/533452

Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii Antibiotic Resistance Mechanisms. Pathogens. 2021;10(3):373. DOI: https://doi.org/10.3390/pathogens10030373

Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of healthcare- and Community-Associated infections with Antimicrobial-Resistant versus Antimicrobial-Susceptible organisms. Clin Infect Dis. 2012;55(6):807-15. DOI: https://doi.org/10.1093/cid/cis552

Sayyahfar S, Choobdar FA, Mashayekhi M, Jazi FM. Successful Management of Pan-Resistant Acinetobacter baumannii Meningitis without Intrathecal or Intraventricular Antibiotic Therapy in a Neonate. Infect Chemotherap. 2021;53(1):146. DOI: https://doi.org/10.3947/ic.2020.0202

Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis. 2009;9(4):245-55.

Rangel K, De-Simone SG. Acinetobacter baumannii during COVID-19: What Is the Real Pandemic? Pathogens. 2022;12(1):41. DOI: https://doi.org/10.3390/pathogens12010041

Korinek AM, Baugnon T, Golmard JL, Van Effenterre R, Coriat P, Puybasset L. Risk factors for adult nosocomial meningitis after craniotomy. Neurosurgery. 2008;62(Suppl 2). DOI: https://doi.org/10.1227/01.neu.0000316256.44349.b1

Moubareck CA, Halat DH. Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen. Antibiotics. 2020;9(3):119. DOI: https://doi.org/10.3390/antibiotics9030119

Falagas ME, Karveli EA, Kelesidis I, Kelesidis T. Community-acquired Acinetobacter infections. Euro J Clin Microbiol Infect Dis. 2007;26(12):857-68. DOI: https://doi.org/10.1007/s10096-007-0365-6

Mangukiya PD, Patel VA, Parmar AT. Prevalence of Enterococcus Species in Various Clinical Specimens and it’s Antimicrobial Susceptibility Pattern in a Tertiary Care Teaching Hospital of Central Gujarat. GAIMS J Med Sci. 2025;5(1):18-24.

Hussein AS, Shafran SD. Acute Bacterial Meningitis in Adults: A 12-Year Review. Medicine. 2000;79(6):360-8. DOI: https://doi.org/10.1097/00005792-200011000-00002

Cavallo I, Oliva A, Pages R, Sivori F, Truglio M, Fabrizio G, et al. Acinetobacter baumannii in the critically ill: complex infections get complicated. Front Microbiol. 2023;14:1196774. DOI: https://doi.org/10.3389/fmicb.2023.1196774

Zong Z, Wu A, Hu B. Infection control in the era of antimicrobial resistance in China: progress, challenges, and opportunities. Clin Infect Dis. 2020;71(Suppl_4):S372-8. DOI: https://doi.org/10.1093/cid/ciaa1514

Li T, Sheng M, Gu T, Zhang Y, Yirepanjiang A, Li Y. In vitro assessment of cefoperazone-sulbactam based combination therapy for multidrug-resistant Acinetobacter baumannii isolates in China. J Thoracic Dis. 2018;10(3):1370-6. DOI: https://doi.org/10.21037/jtd.2018.02.01

Guo C, Xu S, Yan W. A case of treatment for pulmonary infection caused by multidrug‐resistant Acinetobacter baumannii. Respirol Case Reports. 2024;12(7). DOI: https://doi.org/10.1002/rcr2.1420

Wen DY, Bottini AG, Hall WA, Haines SJ. Infections in neurologic surgery. The intraventricular use of antibiotics. Neurosurg Clin North Am. 1991;3(2):343-54. DOI: https://doi.org/10.1016/S1042-3680(18)30666-1

Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis. 2009;9(4):245-55. DOI: https://doi.org/10.1016/S1473-3099(09)70055-6

Jindal N, Jain S, Bhowmick A, Bhargava V. A Lurking Threat of Community-Acquired Acinetobacter Meningitis—A Rare Case Report from Punjab, India. Medicines. 2022;9(4):27. DOI: https://doi.org/10.3390/medicines9040027